Tectonic gets Phase 1b win in heart condition where Eli Lilly recently failednews2025-01-30T15:23:16+00:00January 30th, 2025|Endpoints News|
Merck stops another Winrevair study early based on positive results from earlier PAH trialnews2025-01-30T11:45:23+00:00January 30th, 2025|Endpoints News|
Roche aims for derisked deals and ruthless portfolio cuts in 2025news2025-01-30T11:41:56+00:00January 30th, 2025|Endpoints News|
Inhibikase shelves Parkinson’s asset after Phase 2 flopnews2025-01-30T11:17:28+00:00January 30th, 2025|Endpoints News|
Exclusive: Fertility startup to begin Phase 3 study of stem cell therapy for IVFnews2025-01-29T20:27:55+00:00January 29th, 2025|Endpoints News|
Lilly cuts mid-stage heart failure and chronic kidney drugnews2025-01-28T23:15:44+00:00January 28th, 2025|Endpoints News|
Leap Therapeutics treks toward pivotal study in colorectal cancer, drops gastric cancernews2025-01-28T16:17:00+00:00January 28th, 2025|Endpoints News|
ITM aims to compete with Novartis after Phase 3 radiopharma winnews2025-01-28T11:52:54+00:00January 28th, 2025|Endpoints News|
Sarepta shares two-year DMD data that may inform Europe decisionnews2025-01-27T20:36:39+00:00January 27th, 2025|Endpoints News|
#ASCOGI25: Bristol Myers shares IO combo data in colorectal cancer; Pfizer still waiting on Braftovi regimen survival figuresnews2025-01-27T16:06:27+00:00January 27th, 2025|Endpoints News|
